Clinical trials: Leishmaniasis, Cutaneous
Cutaneous Leishmaniasis
Feasibility of Integrating Thermotherapy for Treatment of Cutaneous Leishmaniasis in Primary Health Care Setup
This study will look at how feasible it is to use thermotherapy (TT) as a treatment for skin(cutaneous) leishmaniasis (CL) in health centers in the Sodo and South Sodo districts, Ethiopia.
- Trial name
- TTCL (NCT06746350)
- Testing
- Thermotherapy
- Where
- Ethiopia
- Volunteers
- 103 people
- Sponsor
- Armauer Hansen Research Institute, Ethiopia
Cutaneous Leishmaniasis
Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia
Outcomes of patients receiving SSG and Allopurinol combination have never been documented systematically in Ethiopia. Therefore, it is not known how effective this combination is.
- Trial name
- NCT04699383
- Testing
- Sodium Stibogluconate with allopurinol
- Where
- Ethiopia
- Volunteers
- 105 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin.
- Trial name
- NCT02281669
- Testing
- Pentostam
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Kinetoplastid, Skin Diseases, Parasitic
Diagnosis and Treatment of Leishmania Infections
Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural…
- Conditions
- Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis
- Trial name
- NCT00344188
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous Leishmaniases
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
While there are indications that 28 days of miltefosine is not sufficient for treating CL by L. aethiopica, a better understanding of what happens in terms of parasite clearance and drug dosing is lacking.
- Trial name
- OPTIMILEISH (NCT06514560)
- Testing
- Miltefosine
- Where
- Ethiopia
- Volunteers
- 80 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Old World Cutaneous Leishmaniasis
Randomised Clinical Trial in Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan
A four (4) -arm randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alternative treatment options to treat cutaneous…
- Trial name
- NCT04268524
- Testing
- drug: miltefosine with thermotherapy
- Where
- 3 sites in Pakistan
- Volunteers
- 645 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Cutaneous Leishmaniasis
Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
"Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis " has begun in October 2008 at the Laboratory of…
- Trial name
- NCT01301924
- Testing
- Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Oswaldo Cruz Foundation
Cutaneous Leishmaniasis
Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
The efficacy of LtSTA as a skin test antigen depends upon the sensitivity and specificity of the product. This study has been designed to measure the skin test responses to 15, 30, or 50µg doses of LtSTA.
- Trial name
- NCT00633009
- Testing
- Leishmania tropica Skin Test Antigen (LtSTA)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nielsen BioSciences, Inc.
Cutaneous Leishmaniasis
Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.
Cutaneous leishmaniasis (CL) is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence the last two decades. It is estimated that in 2005, about of 20,000 new cases of CL were diagnosed in Colombia.
- Trial name
- NCT00471705
- Testing
- Miltefosine, Thermotherapy, Glucantime®
- Where
- Colombia
- Volunteers
- 437 people
- Sponsor
- Universidad de Antioquia
Leishmaniasis, Cutaneous
Development of Topical Herbal Formulations for Treatment of Cutaneous Leishmaniasis
Infections due to protozoa of the genus Leishmania are a major worldwide skin problem, with high endemicity in developing countries including Pakistan.
- Trial name
- NCT04841239
- Testing
- Herbal topical formulation
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- Jinnah Sindh Medical University
Mucosal Leishmaniasis
Treatment of Mucosal Bolivian Leishmaniasis
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis.
- Trial name
- NCT04799236
- Testing
- Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Cutaneous Leishmaniasis
Miltefosine and GM-CSF in Cutaneous Leishmaniasis
Cutaneous leishmaniasis (CL) standard treatment is done with parenteral pentavalent antimony (Sbv) at the dose of 15-20mg / kg per day for 20 days.
- Trial name
- NCT03023111
- Testing
- Sbv, Miltefosine plus GM-CSF
- Where
- 2 sites in Brazil
- Volunteers
- 300 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Cutaneous Leishmaniases
Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan
This research studies the effect thermotherapy as treatment of Old World CL which is not invasive, non-toxic, and the short treatment. While the current standard treatment comprise daily painful injections with antimonials,
- Trial name
- HECT-CL (NCT03208543)
- Testing
- HECT-CL
- Where
- Pakistan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Medecins Sans Frontieres, Netherlands
Cutaneous Leishmaniasis
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis.
- Trial name
- NCT00257530
- Testing
- Imiquimod
- Where
- 2 sites in Peru
- Volunteers
- 80 people
- Sponsor
- Drugs for Neglected Diseases
Cutaneous Leihmaniasis
Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia
The combination of a half-course of miltefosine and a half-course of antimony will be evaluated for efficacy and tolerance. The combination of miltefosine and antimony is chosen because these are now the two standard agents in…
- Trial name
- NCT00537953
- Testing
- Miltefosine , meglumine antimoniate
- Where
- Bolivia
- Sponsor
- Centro de Investigaciones Bioclínicas de la Fundación Fader
Leishmaniasis, Cutaneous
A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL
This trial is designed to assess the therapeutic efficacy and safety of CHAd63-KH, a new candidate Leishmania vaccine, in patients with persistent PKDL.
- Trial name
- NCT03969134
- Testing
- ChAd63-KH
- Where
- Sudan
- Volunteers
- 86 people
- Sponsor
- University of York
Mucocutaneous Leishmaniasis
Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
This study is a Phase 4, open-label, single group study in which at least 55 evaluable adult male patients undergoing miltefosine treatment for mucocutaneous leishmaniasis will provide semen samples for spermiogram analysis of…
- Trial name
- NCT02431429
- Testing
- Miltefosine
- Where
- Bolivia
- Volunteers
- 55 people
- Sponsor
- Knight Therapeutics (USA) Inc
Cutaneous Leishmaniasis
Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate
The Aim of the trial to evaluate the effectiveness of intralesional ciprofloxacin 0.2% solution as a local injection in treating cutaneous leishmaniasis and compare its effect with intralesional sodium stibogluconate (SSG) 10%…
- Trial name
- NCT06798402
- Testing
- Ciprofloxacin (BAYO9867), sodium stibogluconate (Pentostam)
- Where
- Iraq
- Volunteers
- 80 people
- Sponsor
- Al-Mustafa University College
Old World Cutaneous Leishmaniasis
A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
This Phase 2 study is to determine whether WR279396 with occlusion (a polyurethane dressing) is more effective than WR279396 without occlusion for once daily treatment.
- Trial name
- NCT01536795
- Testing
- WR279,396 with Tegaderm Dressing, WR 279,396 with Gauze and Tape Dressing
- Where
- Tunisia
- Volunteers
- 48 people
- Sponsor
- U.S. Army Medical Research and Development Command
Leishmaniasis
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
The investigators will compare the common treatment for cutaneous leishmaniasis with intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam.
- Trial name
- NCT03009422
- Testing
- Local application pentostam, intra-lisional pentostam, fractional CO2 laser
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center